Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
Reuters NewMedia, Inc. - Friday October 24 2:46 PM EDT
The company said the recruitment problem is due to the impact that new HIV therapies are having on AIDS related infections.
In March 1996, ImmuCell decided not to spend any more internal money on the project, a company spokesman said. Project funding was coming from the Center for Special Immunology, an operator of primary clinics to treat HIV and AIDS patients with the intent of receiving royalties.
The amount spent on the research was not immediately available, but a spokesman said the center did not spend a large amount because patients were not enrolled.
The drug is aimed at treating or preventing cryptosporidoiosis, a parasite that causes diarrhea and dehydration in AIDS patents and other individuals with a compromised immunity system.
Positive developments in other therapies have reduced the need for CyptoGAM in AIDS treatment, a spokesman said.
ImmuCell Corp also said it has received a notice of allowance for a U.S. patent for its water test technology.
971024
RE971015
Copyright © 1997 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .